|
gptkbp:instanceOf
|
gptkb:drug
small molecule
|
|
gptkbp:ATCCode
|
none (as of 2024)
|
|
gptkbp:CASNumber
|
867160-71-2
|
|
gptkbp:chemicalFormula
|
C26H28N4O2
|
|
gptkbp:clinicalTrialPhase
|
Phase III (as of 2014)
|
|
gptkbp:developedBy
|
gptkb:Astellas_Pharma
gptkb:OSI_Pharmaceuticals
|
|
gptkbp:hasInChIKey
|
QJQYQJQYQJQYQJ-UHFFFAOYSA-N
|
|
gptkbp:hasSMILES
|
COc1cc2nccc(Oc3ccc(NC(=O)N4CCN(C)CC4)cc3)cc2cc1OC
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
linsitinib
|
|
gptkbp:indication
|
adrenocortical carcinoma
solid tumors
|
|
gptkbp:intendedUse
|
anticancer agent
|
|
gptkbp:IUPACName
|
1-[4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl]-3-(4-methylpiperazin-1-yl)urea
|
|
gptkbp:mechanismOfAction
|
insulin receptor inhibitor
insulin-like growth factor 1 receptor inhibitor
|
|
gptkbp:molecularWeight
|
428.53 g/mol
|
|
gptkbp:PubChem_CID
|
11626560
CHEMBL1237021
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:status
|
investigational
|
|
gptkbp:synonym
|
ASP-7486
OSI-906
OSI906
|
|
gptkbp:target
|
gptkb:IGF-1R
gptkb:INSR
|
|
gptkbp:trialSponsor
|
gptkb:Astellas_Pharma
gptkb:OSI_Pharmaceuticals
|
|
gptkbp:UNII
|
6Z5B6HVF6O
|
|
gptkbp:bfsParent
|
gptkb:IGF1_receptor
gptkb:IGF-1R
gptkb:insulin-like_growth_factor_1_receptor
|
|
gptkbp:bfsLayer
|
7
|